Egrifta SV
GHRH Analog | Visceral Fat Reduction
DoseGear research brief
Tesamorelin is an FDA-approved synthetic GHRH analog designed for HIV-associated lipodystrophy treatment. It provides selective visceral fat targeting with 15-20% visceral fat reduction in clinical trials while preserving subcutaneous fat.
Subcutaneous injection provides optimal bioavailability for GHRH receptor binding and pulsatile GH release stimulation, selectively targeting visceral adipose tissue while sparing subcutaneous fat.
Compound background
Study windows describe what researchers measured, not when an individual should expect a result.
Engineered GHRH analog developed as a medicine for excess abdominal fat in HIV-associated lipodystrophy.
Visceral-adiposity, HIV-associated liver-fat, and selected cognitive research through endogenous GH and IGF-I stimulation.
Cited studies used 26 weeks, 20 weeks, or 12 months, depending on the indication.
Reference data
Not personalized dosing instructions
Only injectable vial references are shown. Nasal, topical, and unsupported non-vial schedules are excluded.
| Research context | Amount | Frequency | Route |
|---|---|---|---|
| HIV Lipodystrophy (FDA-approved) | 1.4mg | Once daily | SubQ |
| Visceral Fat Reduction | 2mg | Once daily | SubQ |
| Anti-aging/Body Composition | 1-2mg | 5-7x weekly | SubQ |
| NAFLD Treatment | 2mg | Once daily (12 months) | SubQ |
| Cognitive Enhancement | 1mg | Once daily (20 weeks) | SubQ |
Reference cycle
Continuous therapy for maintained benefits
Reference storage
Powder: 20-25°C; Egrifta SV: use immediately; Egrifta WR: room temp up to 7 days
Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV (LIPO-010)
Effects of Tesamorelin in HIV-Infected Patients with Abdominal Fat Accumulation: Randomized Placebo-Controlled Trial with Safety Extension (CTR-1011)
Effects of Growth Hormone-Releasing Hormone on Cognitive Function in Adults with MCI and Healthy Older Adults
Effects of Tesamorelin on Non-Alcoholic Fatty Liver Disease in HIV: A Randomised, Double-Blind, Multicentre Trial
This DoseGear profile combines published scientific literature with lyophilized-vial protocol references. Citations are provided for independent review.
